Christine Jenkins , Andrew P. Dickens , Alexander Evans , Porsche Le Cheng , Florian Heraud , Kerry Hancock , Anita Sharma , Belinda Cochrane , Alexander Roussos , Chantal Le Lievre , John Blakey , Sinthia Bosnic-Anticevich , Victoria Carter , Angelina Catanzariti , Clare Ghisla , Mark Hew , Brian Ko , Thao Le , Paul Leong , Vanessa M. McDonald , David Price
{"title":"Patterns of care in the management of high-risk COPD in Australia (2015–2019): an observational study for the CONQUEST quality improvement program","authors":"Christine Jenkins , Andrew P. Dickens , Alexander Evans , Porsche Le Cheng , Florian Heraud , Kerry Hancock , Anita Sharma , Belinda Cochrane , Alexander Roussos , Chantal Le Lievre , John Blakey , Sinthia Bosnic-Anticevich , Victoria Carter , Angelina Catanzariti , Clare Ghisla , Mark Hew , Brian Ko , Thao Le , Paul Leong , Vanessa M. McDonald , David Price","doi":"10.1016/j.lanwpc.2025.101555","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>We compared the management of patients with ‘high-risk’ COPD in Australia to national/international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST).</div></div><div><h3>Methods</h3><div>Eligible patients in the Optimum Patient Care Research Database Australia were categorized as newly diagnosed (≤12 months after diagnosis), already diagnosed, or patients with potential undiagnosed COPD, in each year from 2015 to 2019. ‘High-risk’ patients had ≥2 COPD exacerbations/exacerbation-like events in the last 24 months. Descriptive statistics for 2019 are reported, along with annual trends.</div></div><div><h3>Findings</h3><div>In 2019, 11.3% (2608/22,985) of eligible patients met high-risk criteria. Most newly diagnosed high-risk COPD patients (71.3%) had no recorded lung function testing within 12 months of diagnosis. 63.6% of new COPD diagnoses had no evidence of supporting spirometry or chest CT, with the remainder having recorded chest CT only. 44.3% of already diagnosed high-risk patients had no recorded inhaled maintenance therapy, although this was recorded for 11.2% of potential undiagnosed patients. Smoking cessation support and pulmonary rehabilitation were recorded for <40% and ≤2% of diagnosed COPD patients respectively.</div></div><div><h3>Interpretation</h3><div>There is substantial opportunity to improve diagnosis, assessment and treatment of patients with COPD in Australia by identifying, reviewing and managing high-risk patients in accordance with evidence-based guidelines and CONQUEST standards.</div></div><div><h3>Funding</h3><div>This study was conducted by <span>Optimum Patient Care Australia Pty Ltd</span> (OPCA) and was partially funded by <span>OPCA and AstraZeneca Pty Ltd</span>. No funding was received by the <span>Observational & Pragmatic Research Institute Pte Ltd</span> (OPRI) for its contribution.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"58 ","pages":"Article 101555"},"PeriodicalIF":7.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health: Western Pacific","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666606525000926","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
We compared the management of patients with ‘high-risk’ COPD in Australia to national/international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST).
Methods
Eligible patients in the Optimum Patient Care Research Database Australia were categorized as newly diagnosed (≤12 months after diagnosis), already diagnosed, or patients with potential undiagnosed COPD, in each year from 2015 to 2019. ‘High-risk’ patients had ≥2 COPD exacerbations/exacerbation-like events in the last 24 months. Descriptive statistics for 2019 are reported, along with annual trends.
Findings
In 2019, 11.3% (2608/22,985) of eligible patients met high-risk criteria. Most newly diagnosed high-risk COPD patients (71.3%) had no recorded lung function testing within 12 months of diagnosis. 63.6% of new COPD diagnoses had no evidence of supporting spirometry or chest CT, with the remainder having recorded chest CT only. 44.3% of already diagnosed high-risk patients had no recorded inhaled maintenance therapy, although this was recorded for 11.2% of potential undiagnosed patients. Smoking cessation support and pulmonary rehabilitation were recorded for <40% and ≤2% of diagnosed COPD patients respectively.
Interpretation
There is substantial opportunity to improve diagnosis, assessment and treatment of patients with COPD in Australia by identifying, reviewing and managing high-risk patients in accordance with evidence-based guidelines and CONQUEST standards.
Funding
This study was conducted by Optimum Patient Care Australia Pty Ltd (OPCA) and was partially funded by OPCA and AstraZeneca Pty Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.
背景:我们将澳大利亚“高风险”COPD患者的管理与国家/国际指南和质量标准进行了比较,包括实现COPD护理标准卓越的质量改进合作倡议(CONQUEST)。方法2015年至2019年,澳大利亚最佳患者护理研究数据库(optimal Patient Care Research Database Australia)每年将符合条件的患者分为新诊断(诊断后≤12个月)、已诊断或潜在未诊断的COPD患者。“高风险”患者在过去24个月内发生≥2次COPD加重/加重样事件。报告了2019年的描述性统计数据以及年度趋势。2019年,11.3%(2608/ 22985)的符合条件的患者符合高危标准。大多数新诊断的高风险COPD患者(71.3%)在诊断的12个月内没有肺功能检测记录。63.6%的新COPD诊断没有肺量测定或胸部CT的支持证据,其余的只有胸部CT记录。44.3%已确诊的高危患者没有记录吸入维持治疗,尽管11.2%的潜在未确诊患者记录了这一情况。分别有40%和≤2%的COPD确诊患者记录了戒烟支持和肺部康复。根据循证指南和CONQUEST标准识别、审查和管理高风险患者,澳大利亚有很大的机会来改善COPD患者的诊断、评估和治疗。本研究由澳大利亚最佳患者护理有限公司(OPCA)进行,部分资金由OPCA和阿斯利康公司提供。观察& &;Pragmatic Research Institute Pte Ltd (OPRI)。
期刊介绍:
The Lancet Regional Health – Western Pacific, a gold open access journal, is an integral part of The Lancet's global initiative advocating for healthcare quality and access worldwide. It aims to advance clinical practice and health policy in the Western Pacific region, contributing to enhanced health outcomes. The journal publishes high-quality original research shedding light on clinical practice and health policy in the region. It also includes reviews, commentaries, and opinion pieces covering diverse regional health topics, such as infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, aging health, mental health, the health workforce and systems, and health policy.